Genmab — November 2018

[bibob]

DDB om aktierne efter midvejdvalget. https://danskebank.dk/privat/news/investeringsnyt/forside---investeringsnyt/chefstrateg---saadan-kan-trumps-valglussing-ramme-dine-aktier

[JKY_VH]

Nordea skriver stort set det samme og anbefaler overvægt af aktier. De forventer, at aktier stille og roligt vil kravle opad fra nu, og om 12 måneder vil have givet et afkast på globale aktier på 10-15 pct.

[bibob]

Håber de får ret JKY :-). Det er sundheds aktier der trækker op over det hele.

[Helge_LarsenPI-redaktør]

Hans-Henrik om Midtvejsvalget: http://www.proinvestor.com/debat/76466

[JKY_VH]

Ja bibob, det kan vi da håbe, og så må Novod godt genvinde tilliden til JvW og Genmab.

[GeorgeBest]

Trump i en nøddeskal https://twitter.com/aljwhite/status/1060224698561318913?s=21

[Nickstar]

Er glad for du har fået HH ind i folden, Helge.

[Helge_LarsenPI-redaktør]

Vi har arbejdet sammen før. Nu fik vi muligheden igen.

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[polle1]

God morgen og god dag

[E_L]

NEJM : Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation https://www.nejm.org/doi/full/10.1056/NEJMoa1807438

[E_L]

"Within 1 week after the initiation of treatment with daratumumab, he no longer required transfusions." ………..wtf

[E_L]

New trial: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) https://clinicaltrials.gov/ct2/show/NCT03734198

[Parasitism]

God morgen

[E_L]

and if you are on twitter , have a look at Natalie Callander‏ @nsc_natalie where she talks about a new trial in preparation for Smoldering , Dara + Len/dex, which she hopes to start Feb19

[E_L]

https://twitter.com/mtmdphd/status/1060287065903034368

[E_L]

God morgen indeed

[E_L]

The SC combo trial adds an extra arm, (D-Kd)
https://clinicaltrials.gov/ct2/history/NCT03412565?A=12&B=13&C=merged

[gentogen]

Thanks El. Og lidt apropos: WM cell lines treated with the ibrutinib + Dara combination, showed significantly more cell death through ADCC, CDC, ADCP and apoptosis relative to single‐agent Dara or ibrutinib. In summary, we are the first to report the in vitro and in vivo anti‐WM activity of Dara. Furthermore, we show a close connection between BCR and CD38 signalling, which can be co‐targeted with ibrutinib + Dara to induce marked WM cell death.(British Journal of Haematology 183(2) · August18